Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone

We present health-related quality of life (HRQoL) data from GADOLIN, comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheson, Bruce D., Trask, Peter C., Gribben, John G., Dimier, Natalie, Kimby, Eva, Lugtenburg, Pieternella J., Thieblemont, Catherine, Wassner-Fritsch, Elisabeth, Launonen, Aino, Sehn, Laurie H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226995/
https://www.ncbi.nlm.nih.gov/pubmed/27900446
http://dx.doi.org/10.1007/s00277-016-2878-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226995/
https://www.ncbi.nlm.nih.gov/pubmed/27900446
http://dx.doi.org/10.1007/s00277-016-2878-5

Ejemplares similares